PharmaDrug Inc. Announces Plans for First-In-Human Clinical Study with PD-001 in Esophageal Cancer
PharmaDrug Inc. plans to conduct a first-in-human study of its lead candidate, PD-001, an enteric-coated cepharanthine-2HCL, in Australia in H2 2023. PD-001 has the potential as a breakthrough therapy ...